Computational design of new protein kinase D 1 (PKD1) inhibitors: homology-based active site prediction, energy-optimized pharmacophore, docking and database screening

Protein kinase D 1 (PKD1) overexpression has a well-validated role in cancer progression and its inhibitors have defined a protective role-play of PKD1 for various cancers such as prostate, pancreatic and noninvasive breast cancers, and more. Therefore, the current research was aimed at designing ne...

Full description

Saved in:
Bibliographic Details
Published in:Molecular diversity 2018-02, Vol.22 (1), p.47-56
Main Authors: Nalini, Chadha, Navriti, Bahia, Malkeet Singh, Kaur, Maninder, Bahadur, Renu, Silakari, Om
Format: Article
Language:English
Subjects:
Amino Acid Sequence
Binding Sites
Biochemistry
Biomedical and Life Sciences
Breast cancer
CAD
Cancer
Catalytic Domain
Computer aided design
Databases, Protein
Drug Design
Inhibitors
Kinases
Life Sciences
Ligands
Models, Molecular
Molecular Conformation
Molecular Docking Simulation
Molecular Dynamics Simulation
Molecular structure
Organic Chemistry
Original Article
Pancreatic cancer
Pharmaceutical sciences
Pharmacy
Polymer Sciences
Protein Binding
Protein Kinase C - antagonists & inhibitors
Protein Kinase C - chemistry
Protein Kinase Inhibitors - chemistry
Protein Kinase Inhibitors - pharmacology
Proteins
Quantitative Structure-Activity Relationship
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Protein kinase D 1 (PKD1) overexpression has a well-validated role in cancer progression and its inhibitors have defined a protective role-play of PKD1 for various cancers such as prostate, pancreatic and noninvasive breast cancers, and more. Therefore, the current research was aimed at designing new PKD1 inhibitors combining different ligand- and structure-based computational drug designing methodologies. Initially, the three-dimensional structure of PKD1’s active site was computationally modeled, corrected using molecular dynamic simulations and validated for docking experiments. The highest active PKD1 inhibitor was used to develop a structure-based energetic pharmacophore (e-pharmacophore) model, and a final model was selected with five structural features (Pmodel_AADHR). Pmodel_AADHR was validated and used for database screening to obtain new hits against PKD1. These newly retrieved hits were docked against our PKD1 protein model, and those displaying essential interactions are reported herein as new hits, which could serve as new leads for cancer research, especially pancreatic cancer.
ISSN:1381-1991
1573-501X
DOI:10.1007/s11030-017-9785-0